Skip to main content
Fig. 5 | BMC Immunology

Fig. 5

From: Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants

Fig. 5

VEGF/VEGFR2 and VEGF/VEGFR1 blocking activities in patients that completed the trial vaccination scheme. a VEGF/VEGFR2 blocking activity according to the different vaccination cohorts. b VEGF/VEGFR1 blocking activity according to the different vaccination cohorts. Patients that has shown at least one serum sample with neutralizing anti-VEGF antibodies were considered with a positive blocking activity on the VEGF/VEGFR1 or VEGF/VEGFR2 bindings

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us